Relative risk reductions by dapagliflozin on CV outcomes were irrespective of baseline eGFR and albuminuria status in T2DM patients who had or were at risk of ASCV, shown in a secondary analysis of DECLARE-TIMI 58.
A pre-specified subgroup analysis of DAPA-HF showed that dapagliflozin reduced the risk of worsening HF events or CV death compared to placebo to a similar extent in men and women.
Adverse pregnancy outcomes (APOs) are associated with future development of CVD. The statement from the American Heart Association gives recommendations for strategies to reduce the long-term CVD risk in women with APOs.
Elevated levels of apoB and non-HDL-c better reflect residual risk for all-cause mortality and MI than LDL-c levels in patients treated with statins.
Prof. Rossignol presents results from two mechanistic studies and analyses from two large SGLT2i trials in HFrEF patients that provide insights in the management of diuretics with SGLT2i therapy.
The ESC/EASD risk model was less accurate in prediction of 10-year CVD and all-cause mortality in patients with T2DM compared to SCORE and most notably to single assessment of NT-proBNP.
Subgroup analyses from DAPA-HF and EMPEROR-Reduced evaluated the effects of dapagliflozin and empagliflozin on CV and kidney outcomes according to baseline kidney function in patients with HFrEF.
Tirzepatide, a dual glucose-dependent insulinotropic peptide/GLP-1 receptor agonist (GIP/GLP-1RA), significantly improved glycemic control and reduced body weight in patients with T2DM.
A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.
What is the mechanism of action resulting in benefit with SGLT2i? Carlos Santos-Gallego discusses the results of the EMPA-TROPISM trial that shows reverse LV remodeling by empagliflozin in non-diabetic HFrEF.
This exploratory analysis from DAPA-HF showed that dapagliflozin, compared to placebo, reduced new-onset T2DM in patients with HFrEF without diabetes at baseline.
The STEP 1 trial demonstrated a 15.3 kg weight loss and a sustained ≥5% reduction in body weight in 86.4% of participants after 68 weeks in individuals with overweight or obesity who were treated with semaglutide once-weekly.